|
Miraculins Inc., a biotechnology company, dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that it has added a Luminex Bio-Plex 200 Protein Array System to its laboratory which will enhance the Company’s capabilities to develop clinical grade immunoassays internally.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, announces today that it will be conducting a 2nd pivotal pre-biopsy screen study for its urine based P2V™ prostate cancer diagnostic test.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, has closed its previously announced private placement (the "Offering") with aggregate gross proceeds to the Company of $625,064.70 from the sale of 4,167,098 units (the "Units") at a price of $0.15 per Unit.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that Stephan J. Frost, PhD, has been appointed Director, Research and Development.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, today announces a non-brokered private placement offering (the “Offering”) of up to 5,000,000 units (“Units”) at a price of $0.15 per Unit for gross proceeds of up to $750,000.
Read More
|
|
|